Superbugs & Superdrugs

The fast-moving and ever-changing world market for anti-infective drugs will be the subject of SMi’s seventh annual Superbugs and Superdrugs Conference.  This year’s event will centre around the evaluation of current developments, in terms of advances in drug discovery, the success of recently implemented projects and pipeline developments.

Issues surrounding Anti-Fungal, Antibacterial and Anti-Viral medications worldwide, will give this year’s event a fantastic cross-section of topics which will help to unearth the hot topics, regulatory issues and outstanding progressions within their respective fields.  With the value of the world market in infectious disease drugs standing at around $20bn, both large and small pharma and biotech companies are taking advantage of the current market conditions, creating a very focussed yet diverse approach.

Your attendance will allow you to benefit from the knowledge of top industry experts and enhance your understanding across many different areas.  This in turn will ensure that you are in the best position to make decisions and judgements on the market, as well as supplying you with direct access to some of the major players currently in your sector.

Benefit from the knowledge of:

• Dr André Bryskier, Head, Clinical Pharmacology, Anti-Infectives, Sanofi-Aventis
• Dr Anita Howe, Associate Director, Infectious Diseases, Wyeth
• Dr Kathryn Bracken, Associate Director, Novartis
• Dr Dean Stamos, Associate Director, Chemistry, Drug Discovery, Vertex Pharmaceuticals
• Dr Nafsika Georgopapadakou, Vice President, Infectious Diseases, MethylGene
• Dr Heike Brötz-Oesterhelt, Senior Scientist, Antibacterial Research, Bayer Healthcare
• Dr Hans-Henrik Kristensen, Head, Anti-Infective Discovery, Novozymes
• Dr William Weiss, Director, Drug Evaluation, Cumbre

• CURRENT PROGRESS IN ANTIBIOTIC RESEARCH: Learn about a unique antibiotic discovery engine and an integrated platform to optimise agents for biofilm activity
Learn about a unique antibiotic discovery engine and an integrated platform to optimise agents for biofilm activity
• NEW & FUTURE DRUG DEVELOPMENTS: Hear about antimicrobial peptides, new classes of inhibitors and drugs in the development pipeline
• STRATEGIES AGAINST RESISTANCE: Examine new ways to combat antibiotic resistance
• UPDATE ON ANTI-VIRALS AND ANTI-FUNGALS: What are the current developments?
• DATA EVALUATION & ANALYSIS: Identify how to apply advances in data-driven antibiotics research and learn how to increase the value of your surveillance data
Examine new ways to combat antibiotic resistance